BIOTECH ASSISTANT / FIELD NOTES

From Classical PKPD to Model-Informed Drug Development: Are “Digital Twins” a New Paradigm?

Academic source · Clinical Pharmacology & Therapeutics

Source published: 2026-05-21 · Event / reporting date: 2026-05-21

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

This perspective examines digital-twin claims against established pharmacometric practice. It argues that individual simulation, sequential updating, and decision-focused uncertainty analysis have longstanding roots in PK/PD modeling. The author emphasizes that fundamental limits, including identifiability, remain relevant despite new terminology.

Why this paper is included

Useful for evaluating modeling claims without confusing a new label with demonstrated predictive performance.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Clinical Pharmacology & Model-Informed Development

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Pharmaron Quotient Sciences Crystal Bio Solutions Frontage Laboratories Altasciences

Explore field companies →Explore literature →

Related updates

2026-11-06European Journal of Drug Metabolism and Pharmacokinetics

Progesterone PopPK study combines machine-learning screening with conventional covariate modeling

A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.

Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-05PharmaIN Corporation

PharmaIN reports Phase 1 multiple-dose PHIN-214 findings in cirrhosis

On November 5, PharmaIN reported conference findings from PHIN-001: 12 participants with Child-Pugh B cirrhosis received PHIN-214; 10 completed 28 days. The issuer described Grade 1–2 treatment-related adverse events and exploratory renal, hemodynamic and PK findings. The ongoing small Phase 1 study does not establish clinical benefit. This is a company conference announcement, not a peer-reviewed paper.

Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-05Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

Companies mentionedEthris ↗

mRNA / LNP Clinical Pharmacology & Model-Informed Development Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗